358 related articles for article (PubMed ID: 26720497)
1. Self-evaluation of Adjuvant Chemotherapy-Related Adverse Effects by Patients With Breast Cancer.
Montemurro F; Mittica G; Cagnazzo C; Longo V; Berchialla P; Solinas G; Culotta P; Martinello R; Foresto M; Gallizioli S; Calori A; Grasso B; Volpone C; Bertola G; Parola G; Tealdi G; Giuliano PL; Aglietta M; Ballari AM
JAMA Oncol; 2016 Apr; 2(4):445-52. PubMed ID: 26720497
[TBL] [Abstract][Full Text] [Related]
2. Self-evaluation of duration of adjuvant chemotherapy side effects in breast cancer patients: A prospective study.
Galizia D; Milani A; Geuna E; Martinello R; Cagnazzo C; Foresto M; Longo V; Berchialla P; Solinas G; Calori A; Grasso B; Volpone C; Bertola G; Parola G; Tealdi G; Giuliano PL; Ballari AM; Aglietta M; Montemurro F
Cancer Med; 2018 Sep; 7(9):4339-4344. PubMed ID: 30030895
[TBL] [Abstract][Full Text] [Related]
3. Symptomatic toxicities experienced during anticancer treatment: agreement between patient and physician reporting in three randomized trials.
Di Maio M; Gallo C; Leighl NB; Piccirillo MC; Daniele G; Nuzzo F; Gridelli C; Gebbia V; Ciardiello F; De Placido S; Ceribelli A; Favaretto AG; de Matteis A; Feld R; Butts C; Bryce J; Signoriello S; Morabito A; Rocco G; Perrone F
J Clin Oncol; 2015 Mar; 33(8):910-5. PubMed ID: 25624439
[TBL] [Abstract][Full Text] [Related]
4. Validity and Reliability of the US National Cancer Institute's Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE).
Dueck AC; Mendoza TR; Mitchell SA; Reeve BB; Castro KM; Rogak LJ; Atkinson TM; Bennett AV; Denicoff AM; O'Mara AM; Li Y; Clauser SB; Bryant DM; Bearden JD; Gillis TA; Harness JK; Siegel RD; Paul DB; Cleeland CS; Schrag D; Sloan JA; Abernethy AP; Bruner DW; Minasian LM; Basch E;
JAMA Oncol; 2015 Nov; 1(8):1051-9. PubMed ID: 26270597
[TBL] [Abstract][Full Text] [Related]
5. Health-related quality of life in early breast cancer.
Groenvold M
Dan Med Bull; 2010 Sep; 57(9):B4184. PubMed ID: 20816024
[TBL] [Abstract][Full Text] [Related]
6. Patient versus clinician symptom reporting using the National Cancer Institute Common Terminology Criteria for Adverse Events: results of a questionnaire-based study.
Basch E; Iasonos A; McDonough T; Barz A; Culkin A; Kris MG; Scher HI; Schrag D
Lancet Oncol; 2006 Nov; 7(11):903-9. PubMed ID: 17081915
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of different recall periods for the US National Cancer Institute's PRO-CTCAE.
Mendoza TR; Dueck AC; Bennett AV; Mitchell SA; Reeve BB; Atkinson TM; Li Y; Castro KM; Denicoff A; Rogak LJ; Piekarz RL; Cleeland CS; Sloan JA; Schrag D; Basch E
Clin Trials; 2017 Jun; 14(3):255-263. PubMed ID: 28545337
[TBL] [Abstract][Full Text] [Related]
8. Comparison of Patient- and Practitioner-Reported Toxic Effects Associated With Chemoradiotherapy for Head and Neck Cancer.
Falchook AD; Green R; Knowles ME; Amdur RJ; Mendenhall W; Hayes DN; Grilley-Olson JE; Weiss J; Reeve BB; Mitchell SA; Basch EM; Chera BS
JAMA Otolaryngol Head Neck Surg; 2016 Jun; 142(6):517-23. PubMed ID: 27149571
[TBL] [Abstract][Full Text] [Related]
9. Clinician versus nurse symptom reporting using the National Cancer Institute-Common Terminology Criteria for Adverse Events during chemotherapy: results of a comparison based on patient's self-reported questionnaire.
Cirillo M; Venturini M; Ciccarelli L; Coati F; Bortolami O; Verlato G
Ann Oncol; 2009 Dec; 20(12):1929-35. PubMed ID: 19622510
[TBL] [Abstract][Full Text] [Related]
10. Mode equivalence and acceptability of tablet computer-, interactive voice response system-, and paper-based administration of the U.S. National Cancer Institute's Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE).
Bennett AV; Dueck AC; Mitchell SA; Mendoza TR; Reeve BB; Atkinson TM; Castro KM; Denicoff A; Rogak LJ; Harness JK; Bearden JD; Bryant D; Siegel RD; Schrag D; Basch E;
Health Qual Life Outcomes; 2016 Feb; 14():24. PubMed ID: 26892667
[TBL] [Abstract][Full Text] [Related]
11. Clinicians versus patients subjective adverse events assessment: based on patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE).
Liu L; Suo T; Shen Y; Geng C; Song Z; Liu F; Wang J; Xie Y; Zhang Y; Tang T; Zhang L; Wang W
Qual Life Res; 2020 Nov; 29(11):3009-3015. PubMed ID: 32564293
[TBL] [Abstract][Full Text] [Related]
12. Visceral osteopathic manipulative treatment reduces patient reported digestive toxicities induced by adjuvant chemotherapy in breast cancer: A randomized controlled clinical study.
Lagrange A; Decoux D; Briot N; Hennequin A; Coudert B; Desmoulins I; Bertaut A
Eur J Obstet Gynecol Reprod Biol; 2019 Oct; 241():49-55. PubMed ID: 31430616
[TBL] [Abstract][Full Text] [Related]
13. Clinical predictors of chemotherapy-induced nausea and vomiting in breast cancer patients receiving adjuvant doxorubicin and cyclophosphamide.
Shih V; Wan HS; Chan A
Ann Pharmacother; 2009 Mar; 43(3):444-52. PubMed ID: 19193584
[TBL] [Abstract][Full Text] [Related]
14. Acceptability of Routine Evaluations Using Patient-Reported Outcomes of Common Terminology Criteria for Adverse Events and Other Patient-Reported Symptom Outcome Tools in Cancer Outpatients: Princess Margaret Cancer Centre Experience.
Albaba H; Barnes TA; Veitch Z; Brown MC; Shakik S; Su S; Naik H; Wang T; Liang M; Perez-Cosio A; Eng L; Mittmann N; Xu W; Howell D; Liu G
Oncologist; 2019 Nov; 24(11):e1219-e1227. PubMed ID: 31409744
[TBL] [Abstract][Full Text] [Related]
15. Cognitive function, fatigue, and menopausal symptoms in breast cancer patients receiving adjuvant chemotherapy: evaluation with patient interview after formal assessment.
Downie FP; Mar Fan HG; Houédé-Tchen N; Yi Q; Tannock IF
Psychooncology; 2006 Oct; 15(10):921-30. PubMed ID: 16477674
[TBL] [Abstract][Full Text] [Related]
16. Effect of Diversion Ileostomy on the Occurrence and Consequences of Chemotherapy-Induced Diarrhea.
Robertson JP; Wells CI; Vather R; Bissett IP
Dis Colon Rectum; 2016 Mar; 59(3):194-200. PubMed ID: 26855393
[TBL] [Abstract][Full Text] [Related]
17. Patient free text reporting of symptomatic adverse events in cancer clinical research using the National Cancer Institute's Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE).
Chung AE; Shoenbill K; Mitchell SA; Dueck AC; Schrag D; Bruner DW; Minasian LM; St Germain D; O'Mara AM; Baumgartner P; Rogak LJ; Abernethy AP; Griffin AC; Basch EM
J Am Med Inform Assoc; 2019 Apr; 26(4):276-285. PubMed ID: 30840079
[TBL] [Abstract][Full Text] [Related]
18. Nursing intervention to enhance outpatient chemotherapy symptom management: Patient-reported outcomes of a randomized controlled trial.
Traeger L; McDonnell TM; McCarty CE; Greer JA; El-Jawahri A; Temel JS
Cancer; 2015 Nov; 121(21):3905-13. PubMed ID: 26194461
[TBL] [Abstract][Full Text] [Related]
19. A randomized study of aprepitant, ondansetron and dexamethasone for chemotherapy-induced nausea and vomiting in Chinese breast cancer patients receiving moderately emetogenic chemotherapy.
Yeo W; Mo FK; Suen JJ; Ho WM; Chan SL; Lau W; Koh J; Yeung WK; Kwan WH; Lee KK; Mok TS; Poon AN; Lam KC; Hui EK; Zee B
Breast Cancer Res Treat; 2009 Feb; 113(3):529-35. PubMed ID: 18327706
[TBL] [Abstract][Full Text] [Related]
20. Impact of group psychotherapy in chemotherapy induced vomiting for treatment of advanced breast and lungs cancer.
Parvez T; Alharbi TM; Mein FD
J Coll Physicians Surg Pak; 2007 Feb; 17(2):89-93. PubMed ID: 17288854
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
